Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-31), Grey Wolf Health's 14-Day RSI is 45.03.
The industry rank for Grey Wolf Health's 14-Day RSI or its related term are showing as below:
TSXV:WOLF's 14-Day RSI is ranked better than 56.73% of 1047
companies
in the Drug Manufacturers industry
Industry Median: 46.88
vs TSXV:WOLF: 45.03
Grey Wolf Health (TSXV:WOLF) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Grey Wolf Health 14-Day RSI Related Terms
TSXV:WOLF vs ZTS: 14-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grey Wolf Health's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grey Wolf Health 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grey Wolf Health's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Grey Wolf Health's 14-Day RSI falls into.
Grey Wolf Health (TSXV:WOLF) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grey Wolf Health (TSXV:WOLF) has a 14-Day RSI of 45.03 as of Jul. 31, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Grey Wolf Health and its competitors. According to the industry distribution chart, Grey Wolf Health ranks #453 out of 1047 companies in the Drug Manufacturers industry, placing it in the top 43.3%.
Is Grey Wolf Health's 14-Day RSI too high?
Grey Wolf Health's current 14-Day RSI is 45.03. The Drug Manufacturers industry median 14-Day RSI is 46.88. Grey Wolf Health's value of 45.03 is 3.9% below this industry median. Based on the distribution chart, Grey Wolf Health ranks #453 out of 1047 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grey Wolf Health has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Grey Wolf Health's 14-Day RSI compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Grey Wolf Health ranks #453 out of 1047 companies for 14-Day RSI. This puts Grey Wolf Health in the upper half of its industry. The industry median 14-Day RSI is 46.88. Grey Wolf Health's value of 45.03 is 3.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 46.88, based on 1,047 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grey Wolf Health's current 14-Day RSI of 45.03 is 3.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Grey Wolf Health and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 46.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grey Wolf Health's current 14-Day RSI is 45.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grey Wolf Health stock overvalued right now?
Based on GuruFocus' analysis, Grey Wolf Health (TSXV:WOLF) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.09, compared to a current price of C$1.64 — trading 50.5% above its estimated fair value. The current 14-Day RSI is 45.03 and 3.9% below the Drug Manufacturers industry median of 46.88. Grey Wolf Health's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Grey Wolf Health (TSXV:WOLF), the current 14-Day RSI is 45.03 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grey Wolf Health (TSXV:WOLF) Overvalued in 2026?
Based on GuruFocus' analysis, Grey Wolf Health stock appears to be overvalued.
The current stock price of C$1.64 is trading 50.5% above its estimated GF Value™ of C$1.09.
GuruFocus considers Grey Wolf Health to be Significantly Overvalued.
Key valuation signals for TSXV:WOLF:
14-Day RSI: 45.03
GF Value™: C$1.09 vs. price of C$1.64 (50.5% above fair value)
Industry Position: 3.9% below the Drug Manufacturers median (#453 of 1047)
No single metric tells the full story. See the TSXV:WOLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grey Wolf Animal Health Corp focuses on sourcing, in-licensing, acquiring, and compounding branded and generic products for sale in both animal and human health markets in Canada. The Company operates through two reportable segments: the Animal Health segment, which involves the sale, marketing, and distribution of pharmaceutical, nutraceutical, and consumable products to veterinary clinics across Canada; and the Pharmacy segment, which generates the majority of revenue and focuses on compounding pharmaceuticals for both human and animal health markets.
52GF Score
Get the complete analysis for TSXV:WOLF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:WOLF has been successfully added to your 
